Abstract: The invention relates to benzopyran compounds of formula (I) possessing pharmacological activity, as well as to pharmaceutical compositions containing the compounds of formula (I) and processes for the preparation thereof.

Abstract: A solid, non-hygroscopic salt of the Formula (I) ##STR1## wherein R.sup.1 is dydroxy or alkyl;A is C.sub.1 to C.sub.

Abstract: Controlled release pharmaceutical preparations are prepared by homogenizing an organic or inorganic pharmaceutical active substance such as an opium alkaloid or its salts, an opium antagonist or its salts, an aliphatic or aromatic amine derivative or its salts, a phenolate type medicament, or Zn, Fe, Mg, K, Na salts, a fatty acid or its salt necessary to achieve a continuous phase transfer and an ethylene vinyl acetate copolymer and formulating the resulting homogeneous mixture bya) direct compressing orb) admixing with a solvent orc) using a second, auxiliary polymer.The preparations are suitable for oral or rectal administration or for tissue implantation.

Abstract: The present invention relates to novel morphinane-skeletoned compounds of the formula (I) ##STR1## wherein Y in-NH phenyl or --NH dintro phenyl, Z is --CH.sub.2 -- CH.sub.2, R.sub.2 is hydroxyl and R.sub.3 is H or methyl, the steric isomers and the pharmaceutically acceptable salts thereof, a novel process for producing the same and pharmaceutical compositions comprising the same as active ingredients.The novel compounds can be used in the therapy as analgetic or morphine-antagonistic agents.

Abstract: A process is disclosed for the preparation of (.+-.)-6-cyano-3,4-dihydro-2,2-dimethyl-trans-4-(2-oxo-1-pyrrol idino)-2H-1-benzopyran-3-ol of the Formula (VI) ##STR1## from 4-cyanophenol of the Formula (I) ##STR2## which comprises reacting 4-cyanophenol of the Formula (I) with isoprene, followed with bromination and dehydrobromination steps with formation of intermediates to react with 2-pyrrolidone resulting in obtaining the compound of the Formula (VI).

Abstract: The invention relates to novel, herbicidally active 2-[4-(5-trifluoromethyl-2-pyridyloxy)phenoxy]-propionic acid derivatives of the general formula (I), ##STR1## The invention also relates to herbicide compositions containing the compounds of the general formula (I) as active ingredients as well as to a process for the preparation of these compounds and compositions.

Abstract: The present invention relates to a process for the preparation of methyl-quinoline derivatives, useful as meflocin intermediates, of the formula (I) ##STR1## or salts thereof, wherein X.sup.1 stands for hydrogen or a non-binding electron pair,R.sup.1 stands for hydrogen or a group of the formula (II) ##STR2## R.sup.2 stands for acyloxy or hydroxyl and the dotted line indicates an optionally aromatic ring.

Abstract: The invention relates to a processes for the preparation of quinoline derivatives of the general formula (I) ##STR1## wherein R.sup.1 stands for hydrogen or a group of the formula (II) ##STR2## which are intermediates for pharmaceutically active compounds.

Abstract: A process is disclosed for the preparation of (.+-.)-6-cyano-3,4-dihydro-2,2-dimethyl-trans-4-(2-oxo-1-pyrrol idino)-2H-1-benzopyran-3-ol of the Formula (VI) ##STR1## from 4-cyanophenol of the Formula (I) ##STR2## which comprises reacting 4-cyanophenol of the Formula (I) with isoprene, followed with bromination and dehydrobromination steps with formation of intermediates to react with 2-pyrrolidone resulting in obtaining the compound of the Formula (VI).

Abstract: A process is provided for the quantitative selective complexometric analysis of a sample. First and second aliquot parts of a sample containing N-phosphonomethyl-glycine, N-carboxymethyl-N-phosphonomethyl-glycine or N,N-bis-phosphonomethyl-glycine; or N-phosphonomethyl-glycine and N,N-bis-phosphonomethyl-glycine; or N-phosphonomethyl-glycine and N-carboxymethyl-N-phosphonomethyl-glycine are taken. The first aliquot part is titrated with a bismuth volumetric solution at a Ph=1.8-2.5 in the presence of a methylethymol blue indicator. The second aliquot part is titrated with a copper volumetric solution at a Ph=8-10 in the presence of a murexide indicator. Two end point values are obtained and compared. The difference between these two values result in the determination of the content of N-phosphonomethyl-glycine in the sample.

Abstract: The invention relates to new triazolyl quinoline derivatives and acid addition salts thereof whereinR.sup.1 stands for hydrogen, methyl, trihalogenomethyl or carboxy;R.sup.2 is hydrogen, halogen, C.sub.1-4 alkyl, hydroxy, C.sub.1-4 alkoxy, phenoxy, amino, acetamino, C.sub.1-4 dialkylamino, acetyl, benzoyl, methylthio, carboxy, cyano, ethoxycarbonyl, nitro or trihalogenomethyl;R.sup.3 represents hydrogen, C.sub.1-4 alkyl or C.sub.1-4 alkoxy;R.sup.4 stands for hydrogen, methyl or ethyl andX stands for a valency bond or --S--.The new compounds of the general Formula (I) ##STR1## possess valuable analgesic, antiphlogistic and fungicidal effect and can be used both in therapy and agriculture.

Abstract: The invention refers to new diamines of the Formula I ##STR1## wherein R stands for ##STR2## or --NH--COA.sup.1 --R.sup.4 or ##STR3## wherein A stands for C.sub.1-5 alkylene which can be substituted by hydroxyl,X stands for a single or double bond,R.sup.2 stands for aryl or heteroaryl optionally substituted by halogen, C.sub.1-4 alkoxy or acylamino,R.sup.3 stands for hydrogen or C.sub.1-4 alkyl,A.sup.1 stands for a single bond or C.sub.1-5 alkyl optionally substituted by hydroxyl or thioalkylene or oxyalkylene,R.sup.4 stands for a 5- or 6- membered aromatic or heteroaromatic ring which can be substituted by one or more hydroxyl, C.sub.1-4 alkyl and/or C.sub.1-4 alkoxy and/or halogen or methylenedioxy and the alkyl group can be unsaturated as well,Q stands for a 6-membered ring which can be partially hydrogenated, andR.sup.1 stands for C.sub.1-4 alkyl.The new compounds are antiarrhythmic agents.

Abstract: The invention refers to new diamines of the Formula I ##STR1## wherein R stands for ##STR2## wherein A stands for C.sub.1-5 alkylene which can be substituted by hydroxyl,X stands for a single or double bond,R.sup.2 stands for aryl or heteroaryl optionally substituted by halogen, C.sub.1-4 alkoxy or acylamino,R.sup.3 stands for hydrogen or C.sub.1-4 alkyl,A.sup.1 stands for a single bond or C.sub.1-5 alkyl optionally substituted by hydroxyl or thioalkylene or oxyalkylene,R.sup.4 stands for a 5- or 6- membered aromatic or heteroaromatic ring which can be substituted by one or more hydroxyl, C.sub.1-4 alkyl and/or C.sub.1-4 alkoxy and/or halogen or methylenedioxy and the alkyl group can be unsaturated as well,Q stands for a 6-membered ring which can be partially hydrogenated, andR.sup.1 stands for C.sub.1-4 alkyl.The new compounds are antiarrhythmic agents.

Abstract: The invention relates to a process for the preparation of Chromenes of the general Formula V ##STR1## prepared from chromanone derivatives.

Abstract: The invention refers to new diamines of the Formula I ##STR1## wherein stands for ##STR2## wherein A stands for C.sub.1-5 alkylene which can be substituted by hydroxyl,X stands for a single or double bond,R.sup.2 stands for aryl or heteroaryl optionally substituted by halogen, C.sub.1-4 alkoxy or acylamino,R.sup.3 stands for hydrogen or C.sub.1-4 alkyl,A.sup.1 stands for a single bond or C.sub.1-5 alkyl optionally substituted by hydroxyl or thioalkylene or oxyalkylene,R.sup.4 stands for a 5- or 6- membered aromatic or heteroaromatic ring which can be substituted by one or more hydroxyl, C.sub.1-4 alkyl and/or C.sub.1-4 alkoxy and/or halogen or methylenedioxy and the alkyl group can be unsaturated as well,Q stands for a 6-membered ring which can be partially hydrogenated, andR.sup.1 stands for C.sub.1-4 alkyl.The new compounds are antiarrhythmic agents.

Abstract: The invention relates to a process for the preparation of chromenes of the general Formula V ##STR1## (wherein R.sup.1 and R.sup.2 are hydrogen, optionally halogeno substituted C.sub.1-6 alkyl or aryl;R.sup.3 and R.sup.7 stand for hydrogen, halogen or C.sub.1-6 alkyl;R.sup.4 represents C.sub.1-8 alkyl, aryl, aralkyl or a group containing a carbonyl group;R.sup.5 and R.sup.6 stand for C.sub.1-10 alkyl, aryl, amino, hydroxyalkyl, alkoxyalkenyl, alkylmercaptoalkyl, acyl, carboxy or an ester group or a halogen atom;n is 0 or 1)which comprises(a) for the preparation of compounds, in which R.sup.5 and R.sup.6 stand for different groups, reacting a compound of the general Formula I ##STR2## with an approximately equimolar, preferably 0.8-1.5 molar amount of a reactant of the general Formula R.sup.5 --X-related to the amount of the compound of the general Formula I (wherein R.sup.

Abstract: The invention relates to new substituted dihydropyridine derivatives of the general formula (I), ##STR1## wherein R.sup.1 and R.sup.6 are as defined herein after, the racemic and optically active variants as well as mixtures thereof, furthermore the acid addition salts of these compounds, pharmaceutical compositions containing the same and a process for the preparation thereof.The compounds of the general formula (I) can be advantageously applied for the treatment of pathologically severe hypertensions, their toxicity is low and they possess an advantageous therapeutic index.

Abstract: Compounds are disclosed of the formula (I) ##STR1## wherein A.sup.1 is a valence bond or a C.sub.1 to C.sub.5 straight or branched chain alkylene group unsubstituted or substituted by hydroxy or aminocarbonyl;B is a valence bond or a double bond;R.sup.3 is hydrogen or C.sub.1 to C.sub.4 alkyl;R.sup.2 is a phenyl or phenoxy group unsubstituted or substituted by one or two C.sub.1 to C.sub.4 alkyl groups, C.sub.1 to C.sub.4 alkoxy groups, or halo substituents; or R.sup.2 is an amino group, a diphenylmethyl group, or an R.sup.4 --NH--CO-- group in whichR.sup.4 is 2,6-dimethyl-phenyl; or a pharmaceutically acceptable acid addition salt thereof. The compounds possess anti-arrhythmic activity and exert little or no hypotensive side effects.

Abstract: The invention relates to pesticidal compositions comprising as active ingredient a compound of the general Formula I ##STR1## wherein R.sup.1 and R.sup.2 stand for hydrogen, optionally halogenosubstituted C.sub.1-6 alkyl or aryl;R.sup.3 and R.sup.4 are hydrogen, halogen or C.sub.1-6 alkyl;R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are hydrogen, hydroxy, mercapto, amino, C.sub.1-10 alkyl; a group containing a methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec. butoxy, isobutoxy, tert. butoxy, n-pentyloxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, cyclooctyloxy, allyloxy, crotyloxy, prenyloxy, propargyloxy, substituted propargyloxy, C.sub.1-3 alkylenedioxy, aralkoxy, substituted aralkoxy, hydroxyalkoxy, alkoxyalkoxy, mercaptoalkoxyalkoxy, halogenoalkoxy, dihalogenoalkoxy, trihalogenoalkoxy, polyhalogenoalkoxy, N,N-dialkylaminoalkoxy, cycloalkylaminoalkoxy, alkylenoxy-alkyleneoxy, alkylene-thia-alkylenoxy or alkylene-aza-alkylenoxy unit or C.sub.

Abstract: The present invention relates to pharmaceutical compositions comprising 3-dimethylamino-7-methyl-1,2-(n-propylmalonyl)-1,2-dihydro-1,2,4-benzotria zine and at least one of a factor of Vitamine P and/or (+)-2-(3,4-dihydroxyphenyl)-3,5,7-cromanetriole as active ingredients, a process for preparing the same and a method for treating pancreatic inflammations with the said composition.The pharmaceutical compositions according to the invention are useful for the treatment of pancreatic inflammations.